 Home > Biochemistry News > Biotechnology News > NICE recommends Opdivo for removal of cancer of the esophagus or gastroesophageal junction

NICE recommends Opdivo for removal of cancer of the esophagus or gastroesophageal junction

 Last Update: 2021-11-04
 Source: Internet
 Author: User

Tags

1 3 ml

januvia drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

Recently, the National Institute of Health and Care Excellence (NICE) in the United Kingdom has recommended Bristol-Myers Squibb Opdivo (nivolumab) as a treatment option for certain patients with esophagus resection or gastroesophageal junction (GEJ)
.

As a result, Opdivo has been approved as an adjuvant treatment for complete resection of esophageal cancer or GEJ cancer in adults with residual disease after neoadjuvant radiotherapy and chemotherapy
.

In May of this year, the drug was approved by the U.

According to a randomized double-blind, placebo-controlled phase 3 CHECKMATE-577 trial, the results showed that compared with the placebo group, the disease-free survival (DFS) of patients treated with Opdivo showed a statistically significant improvement
.

The median DFS in the Opdivo group was 22.

The two main types of esophageal cancer are squamous cell carcinoma and adenocarcinoma.
Squamous cell carcinoma usually affects the upper and middle esophagus, while adenocarcinoma usually occurs in the lower esophagus, including the gastroesophageal junction
.

British NICE added in a statement that Opdivo has the potential to extend people's overall lifespan more effectively, although there is no clinical trial evidence to prove this

Up to now, Opdivo has been approved to treat a variety of tumors in the UK
.

Just 4 months ago, NICE in the United Kingdom issued a final evaluation document, approving Bristol-Myers Squibb’s anti-PD-1 therapy Opdivo for the treatment of advanced esophageal squamous cell carcinoma (OSCC) that has failed chemotherapy and cannot be surgically removed

Reference source: NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.